In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

The prognostic value of myocardial fibrosis MRI in assessing the risk of progression of heart failure in patients with HCM

Session Poster Session 3

Speaker Olesya Shatova

Congress : Heart Failure 2019

  • Topic : arrhythmias and device therapy
  • Sub-topic : Hypertrophic Cardiomyopathy
  • Session type : Poster Session
  • FP Number : P1818

Authors : O Shatova (Minsk,BY), E Zakharova (Minsk,BY), S Komissarova (Minsk,BY), E Vankovich (Minsk,BY), I Haidzel (Minsk,BY)

O Shatova1 , E Zakharova1 , S Komissarova1 , E Vankovich1 , I Haidzel1 , 1Republican Scientific and Practical Centre of Cardiology, heart failure - Minsk - Belarus ,


The progression of symptoms of CHF is still a serious complication that determines the outcome in HCM. It should be noted that in most cases in patients with HCM with symptoms of severe CHF, LVEF remains preserved, which requires a search for new diagnostic approaches to assess the systolic function of the myocardium.
Purpose: to assess the prognostic role of myocardial fibrosis volume by gadolinium contrast-enhanced MRI in patients with HCM as a predictor of CHF progression to FC III NYHA, which required hospitalization.
Methods. The study included 124 patients with HCM (79 males and 45 females) aged 18 to 69 years (median age 46 years), median observation 42 months (3.5 years). The clinical end point included the progression of CHF symptoms from I – II FC to NYHA FC III, requiring hospitalization.
Results. Among 124 patients, the progression of CHF symptoms requiring hospitalization was observed in 24 people and occurred in the presence of preserved systolic function (LV EF> 50 %). 12 patients were hospitalized for two years, which indicates the rapid progression of symptoms of heart failure with NYHA FC I-II to FC III. The cumulative 3-year survival rate was 83 % (95% CI 76.5 - 90.1). The one-factor regression analysis was performed to determine the predictors of the progression of CHF symptoms and hospitalizations. As a new marker aimed at identifying patients at risk of adverse events, myocardial fibrosis volume was analyzed by MRI. Kaplan-Meier curve-free survival showed statistically significant differences in groups with a fibrosis volume of less than 20% and more than 20 % (log-rank p <0.001) and amounted to 95.2 % (95% CI 89.9 -100 %) and 32.1 % (95 % CI 17.9 -57.4 %), respectively. All indicators that were statistically significant in univariate regression analysis were included in the multivariate analysis and their threshold values were determined. In a multivariate analysis, independent factors associated with the progression of CHF and related hospitalization were the following characteristics: age> 50 years old (RR 5.9; 95 % CI 2.3–15.1, p <0.001), presence of episodes of AF (RR 5.6 ; 95% CI 2.2 - 14.2, p <0.001) and the volume of myocardial fibrosis by MRI  = 20  % (RR 23.3; 95% CI 7.3 - 74.8, p <0.001). The regression analysis identified a group of patients with HCM, potentially having the risk of progression of CHF, which required hospitalization, with age> 50 years, episodes of AF and the amount of fibrosis = 20%.
Conclusion. Myocardial fibrosis index = 20% is associated with the development of adverse events associated with the progression of CHF in HCM and can be used to identify patients at high risk of developing CHF progression with an unfavorable outcome.

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are